SLC5A2 and Stroke: The results of the EMPA-REG OUTCOME trial169 were a major breakthrough in the field, showing a significant 14% relative risk reduction in the rate of the composite primary end point, including cardiovascular death, MI, or stroke, with empagliflozin, an inhibitor of the sodium/glucose cotransporter 2 (SGLT2), causing glycosuria.